NCT00086164终止1 期
A Phase 1/2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Pilot Trial to Assess the Effect of Treatment of the Recipient Vein of a Polytetrafluoroethylene (PTFE) Vascular Access Graft With Two Concentrations of E2F Decoy as Compared to Placebo on Neointimal Hyperplasia and the Preservation of Graft Function in Patients With Chronic Renal Failure Requiring Hemodialysis
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 试验地点
- 40
研究概览
简要总结
The purpose of this study is to determine the effect of recipient vein pretreatment of edifoligide (E2F Decoy), compared to placebo, on graft/recipient vein stenosis in polytetrafluoroethylene (PTFE) vascular access grafts placed for hemodialysis at 6 months after enrollment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 79 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Be scheduled to undergo placement of a new straight or loop arm PTFE arteriovenous hemodialysis access graft or a Vectragraft® (Thoratec, Inc.)
- •Be currently receiving chronic dialysis or be expected to begin hemodialysis within 4 weeks of placement of the index PTFE graft
- •Have undergone an assessment of patency (such as venography) of central veins if any of the following conditions have occurred on the ipsilateral arm intended for graft placement: presence of collateral veins, upper extremity edema or increased size (relative to the contralateral arm), history of subclavian catheter, transvenous pacemaker, or history of trauma or surgery that may have involved the neck or chest veins
- •Be > 18 and <80 years old
- •Have a documented negative serum pregnancy test (for all women of childbearing potential)
- •Be using an acceptable method of birth control if of reproductive potential and agree to continue using the birth control for at least 3 months following the graft procedure
- •Have agreed to participate voluntarily and have signed and dated an IRB/EC approved, Patient Informed Consent form
排除标准
- •Have an intended recipient vein >6 mm or <3 mm in diameter
- •Have a history of three or more previous PTFE grafts
- •Have uncorrected central vein (including the subclavian vein) stenosis
- •Have markedly diminished arterial pulses in the access location (unless adequate flow has been documented by arteriography or Doppler ultrasound)
- •Anticipate receipt of a renal transplant within 6 months of enrollment into this study
- •Have anticipated use of the index PTFE graft <14 days after enrollment (this does not apply to Vectragraft®)
- •Have a known allergy to iodinated contrast
- •Have a known hypercoagulable state (e.g., antithrombin III deficiency; antiphospholipid or anticardiolipin antibodies; Factor V Leiden; circulating lupus anticoagulant; current, active, heparin-induced thrombocytopenia; Protein C or S deficiency; or a history of recurrent deep venous thrombosis not related to AV access)
- •Have been in another investigational (i.e., nonapproved) drug or device study within the previous 30 days or prior participation in another clinical study with E2F Decoy
- •Have been previously enrolled in this study for an earlier access graft
- •Have any comorbid, nonrenal condition that makes 6-month survival questionable (e.g., end-stage cancer, advanced heart failure)
- •Have a known or suspected history of drug or alcohol abuse within the previous 6 months
- •Have a known allergy to any component of the investigational product (drug or device), including latex
研究者
研究点 (40)
Loading locations...
相似试验
已完成
2 期
Prevention of Autogenous Vein Graft Failure in Peripheral Artery Bypass ProceduresPeripheral Vascular DiseasesArterial Occlusive DiseasesIschemiaGraft Occlusion, VascularHyperplasiaNCT00041925Anesiva, Inc.1,400
已完成
3 期
Endovascular Treatment With or Without Preceding Intravenous Tenecteplase (TNK) in Patients With Late-window acUte Ischemic Stroke Due to Middle Cerebral Artery OcclusionIschemic Stroke, AcuteThrombolysisEndovascular TreatmentNCT06221371Beijing Tiantan Hospital391
尚未招募
Unknown
To evaluate the efficacy of pretreatment of vein with plain intravenous lignocaine before propofol with that of premixed solution of lignocaine and propofol to decrease pain on injection during propofol induction of anaesthesia:CTRI/2024/04/065103I
已完成
不适用
Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to LucentisWet AMDNCT00804934Retina Institute of Hawaii100
已完成
不适用
Effects of venodilation technique for peripheral intravenous cannulation(the effect of thermal stimulus)health general peopleJPRN-UMIN000021106Graduate school of medicine Osaka University70